Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-09-24
DOI
10.3389/fonc.2018.00369
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
- (2017) M Abraham et al. LEUKEMIA
- A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
- (2017) Nicholas J. Short et al. LEUKEMIA & LYMPHOMA
- A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer
- (2017) Ravi Salgia et al. LUNG CANCER
- A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
- (2017) G L Uy et al. Blood Cancer Journal
- Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
- (2017) Sheng-Bin Peng et al. Oncotarget
- Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang
- (2016) Hong-Sheng Zhou et al. Cancer Biology & Medicine
- Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy
- (2015) B.-S. Cho et al. BLOOD
- Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation
- (2015) M Konopleva et al. BONE MARROW TRANSPLANTATION
- Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience
- (2014) Naveen Pemmaraju et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
- (2014) M. D. Galsky et al. CLINICAL CANCER RESEARCH
- International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- (2014) Gail J. Roboz et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
- (2014) S.-B. Peng et al. MOLECULAR CANCER THERAPEUTICS
- Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience
- (2013) Wenjuan Yu et al. ANNALS OF HEMATOLOGY
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients
- (2012) Barbara Scappini et al. AMERICAN JOURNAL OF HEMATOLOGY
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
- (2012) G. L. Uy et al. BLOOD
- Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia
- (2012) Elias Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia
- (2012) Khanh Vu et al. Clinical Lymphoma Myeloma & Leukemia
- CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model
- (2012) Y Zhang et al. Cell Death & Disease
- Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
- (2011) Pamela S. Becker et al. BRITISH JOURNAL OF HAEMATOLOGY
- CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
- (2010) Katia Beider et al. EXPERIMENTAL HEMATOLOGY
- FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation
- (2010) Michael Brave et al. ONCOLOGY
- Inhibition of the SDF-1 -CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice
- (2009) A. Kawaguchi et al. BLOOD
- Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
- (2009) Mark R. Litzow et al. BRITISH JOURNAL OF HAEMATOLOGY
- Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
- (2008) B. Nervi et al. BLOOD
- Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia
- (2008) F A Fierro et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now